Td Asset Management Has Upped By $2.31 Million Its Celanese Del (CE) Stake; Calithera Biosciences (CALA) SI Increased By 10.21%

January 14, 2018 - By Louis Casey

Calithera Biosciences Incorporated (NASDAQ:CALA) had an increase of 10.21% in short interest. CALA’s SI was 3.88M shares in January as released by FINRA. Its up 10.21% from 3.52 million shares previously. With 810,800 avg volume, 5 days are for Calithera Biosciences Incorporated (NASDAQ:CALA)’s short sellers to cover CALA’s short positions. The SI to Calithera Biosciences Incorporated’s float is 29.62%. The stock decreased 0.58% or $0.05 during the last trading session, reaching $8.55. About 238,845 shares traded. Calithera Biosciences, Inc. (NASDAQ:CALA) has risen 278.82% since January 14, 2017 and is uptrending. It has outperformed by 262.12% the S&P500.

Td Asset Management Inc increased Celanese Corp Del (CE) stake by 10.54% reported in 2017Q3 SEC filing. Td Asset Management Inc acquired 22,234 shares as Celanese Corp Del (CE)’s stock declined 5.81%. The Td Asset Management Inc holds 233,267 shares with $24.32M value, up from 211,033 last quarter. Celanese Corp Del now has $15.10B valuation. The stock increased 0.06% or $0.07 during the last trading session, reaching $111.34. About 452,611 shares traded. Celanese Corporation (NYSE:CE) has risen 21.48% since January 14, 2017 and is uptrending. It has outperformed by 4.78% the S&P500.

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company has market cap of $303.33 million. The Company’s lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase Ib/2 clinical trials for the treatment of solid tumors. It currently has negative earnings. The firm has a license agreement with Mars, Inc. to develop and commercialize SymbioscienceÂ’s portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors.

Investors sentiment decreased to 1.22 in Q3 2017. Its down 2.03, from 3.25 in 2017Q2. It worsened, as 16 investors sold Calithera Biosciences, Inc. shares while 21 reduced holdings. 14 funds opened positions while 31 raised stakes. 25.24 million shares or 49.47% less from 49.95 million shares in 2017Q2 were reported. Teachers Retirement Sys Of The State Of Kentucky stated it has 27,600 shares. Atika Cap Limited Liability Corporation invested in 1.06% or 234,603 shares. Strs Ohio invested in 3,600 shares. 23,000 are held by State Of Wisconsin Inv Board. Gam Hldgs Ag accumulated 40,200 shares or 0.03% of the stock. Iconiq Cap Limited has 23,222 shares for 0.04% of their portfolio. Bnp Paribas Arbitrage holds 0% or 3,304 shares in its portfolio. Ny State Common Retirement Fund reported 32,700 shares. The Nebraska-based Ameritas Prtn has invested 0% in Calithera Biosciences, Inc. (NASDAQ:CALA). 42,029 were accumulated by D E Shaw. Barclays Public Ltd Company has 0% invested in Calithera Biosciences, Inc. (NASDAQ:CALA) for 23,851 shares. Tiaa Cref Invest Mngmt Limited Liability, New York-based fund reported 189,115 shares. Ascend Cap Limited Company has invested 0.39% in Calithera Biosciences, Inc. (NASDAQ:CALA). 15,177 are owned by State Board Of Administration Of Florida Retirement Sys. Citigroup reported 57,938 shares.

Among 5 analysts covering Calithera Biosciences (NASDAQ:CALA), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Calithera Biosciences had 9 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Tuesday, January 24 by Citigroup. The firm has “Buy” rating given on Thursday, January 5 by H.C. Wainwright. H.C. Wainwright maintained the shares of CALA in report on Monday, June 12 with “Buy” rating. Citigroup initiated the shares of CALA in report on Friday, July 24 with “Buy” rating. The rating was initiated by Citigroup with “Sell” on Tuesday, October 25. The rating was maintained by JMP Securities with “Market Outperform” on Wednesday, March 9. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, March 28 report.

Investors sentiment decreased to 0.91 in 2017 Q3. Its down 0.15, from 1.06 in 2017Q2. It dived, as 24 investors sold CE shares while 162 reduced holdings. 56 funds opened positions while 114 raised stakes. 126.78 million shares or 3.48% less from 131.35 million shares in 2017Q2 were reported. James owns 630,167 shares for 2.21% of their portfolio. Brandywine Global Investment Management Ltd Com accumulated 156,318 shares. Lord Abbett & Co Limited Co has 0.11% invested in Celanese Corporation (NYSE:CE). Korea Corporation invested 0.05% of its portfolio in Celanese Corporation (NYSE:CE). Investec Asset Mngmt Limited has 4,296 shares for 0% of their portfolio. The Sweden-based Nordea Investment Management has invested 0.15% in Celanese Corporation (NYSE:CE). Financial Architects Incorporated invested in 977 shares. Trust Co Of Vermont accumulated 100 shares. Century Inc holds 0% or 7,376 shares. Ajo LP has 436,088 shares. Wellington Shields Mgmt Lc owns 7,150 shares. Strs Ohio accumulated 11,139 shares. Wellington Management Grp Incorporated Ltd Liability Partnership has 0.14% invested in Celanese Corporation (NYSE:CE). Stephens Ar has 0.02% invested in Celanese Corporation (NYSE:CE). Neuberger Berman Lc holds 2,671 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>